ISCO (International Stem Cell) Accounts Payable: $0.44 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ISCO International Stem Cell Corp ISCO
30 GF Score
Price $0.17
GF Value $0.13
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is International Stem Cell Accounts Payable?

International Stem Cell ISCO -13.21% 30 Accounts Payable is $0.44 Mil as of Mar. 2026. GuruFocus rates ISCO with a GF Score™ of 30/100 and a GF Value™ of $0.13 (Significantly Overvalued). The stock has 5 warning signs investors should review.

International Stem Cell's Accounts Payable for the quarter that ended in Mar. 2026 was $0.44 Mil.

International Stem Cell's quarterly Accounts Payable declined from Sep. 2025 ($0.27 Mil) to Dec. 2025 ($0.17 Mil) but then increased from Dec. 2025 ($0.17 Mil) to Mar. 2026 ($0.44 Mil).

International Stem Cell's annual Accounts Payable declined from Dec. 2023 ($0.36 Mil) to Dec. 2024 ($0.19 Mil) and declined from Dec. 2024 ($0.19 Mil) to Dec. 2025 ($0.17 Mil).

International Stem Cell Accounts Payable Related Terms

International Stem Cell Accounts Payable Historical Data

* Premium members only.

The historical data trend for International Stem Cell's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

International Stem Cell Accounts Payable Chart

International Stem Cell Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.51 0.32 0.36 0.19 0.17

International Stem Cell Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 0.40 0.27 0.17 0.44
ISCO
30GF Score
International Stem Cell Corp ISCO
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

International Stem Cell Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $0.44 Mil mean?
International Stem Cell (ISCO) has a Accounts Payable of $0.44 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on International Stem Cell and its competitors.
Is International Stem Cell's Accounts Payable too high?
International Stem Cell's current Accounts Payable is $0.44 Mil. Overall, International Stem Cell has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does International Stem Cell's Accounts Payable compare to ZVSA and AXIM?
International Stem Cell's Accounts Payable of $0.44 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on International Stem Cell and its competitors. International Stem Cell's current Accounts Payable is $0.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is International Stem Cell stock overvalued right now?
Based on GuruFocus' analysis, International Stem Cell (ISCO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.17 — trading 32.7% above its estimated fair value. The current Accounts Payable is $0.44 Mil. International Stem Cell's overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For International Stem Cell (ISCO), the current Accounts Payable is $0.44 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is International Stem Cell (ISCO) Overvalued in 2026?

Based on GuruFocus' analysis, International Stem Cell stock appears to be overvalued. The current stock price of $0.17 is trading 32.7% above its estimated GF Value™ of $0.13. GuruFocus considers International Stem Cell to be Significantly Overvalued.

Key valuation signals for ISCO:

  • Accounts Payable: $0.44 Mil
  • GF Value™: $0.13 vs. price of $0.17 (32.7% above fair value)
  • GF Score™: 30/100 with 5 warning signs

No single metric tells the full story. See the ISCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

International Stem Cell Business Description

Address 9745 Businesspark Avenue, San Diego, CA, USA, 92131
International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. The company operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.
30GF Score

Get the complete analysis for ISCO

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.17
Price
$0.13
GF Value